ONKURE THERAPEUTICS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
ONKURE THERAPEUTICS, INC. (OKUR) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements of -$590.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-23.
Discontinued › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements · last filed 2022-03-23
- ONKURE THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2021-12-31 was $0.00.
- ONKURE THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2021-09-30 was $0.00.
- ONKURE THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2021 was -$590.00K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $0.00 derived: sum of 2 quarters · filed 2022-03-23 | -$590.00K 10-K · filed 2022-03-23 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$590.00K 10-Q · filed 2021-11-12 | ||
| 2021-06-30 | -$590.00K 10-Q · filed 2021-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |